Apimeds Pharmaceuticals Us Quick Ratio (APUS) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Apimeds Pharmaceuticals US, Inc.  (NYSE: APUS)

Apimeds Pharmaceuticals Us's Quick Ratio

APUS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 1.16 below Apimeds Pharmaceuticals Us's average Quick Ratio.

Within Major Pharmaceutical Preparations industry Apimeds Pharmaceuticals US, Inc. booked the highest Quick Ratio than Apimeds Pharmaceuticals Us in the second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 3 to 4.

Explain Quick Ratio?
How much Cash & cash equivalents APUS´s has?
What are APUS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

APUS Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 2908.5 % 302.32 % 9592.46 % 943.38 % -
Y / Y Cash & cash equivalent Change -5.23 % 4478.11 % 3133.47 % 1601.97 % -
Quick Ratio MRQ 1.16 1.52 1.26 6.15 36.67
APUS's Total Ranking # 4 # 3 # # #
Seq. Current Liabilities Change -4.77 % -28.64 % 828.95 % 376.57 % -87.26 %
Seq. Cash & cash equivalent Change -27.76 % -13.67 % 89.98 % -20.02 % 3389.93 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 0
Overall Market # 4


Quick Ratio Statistics
High Average Low
36.67 6.82 0.27
(Jun 30 2025)   (Mar 31 2025)




Financial Statements
Apimeds Pharmaceuticals Us's Current Liabilities $ 7 Millions Visit APUS's Balance sheet
Apimeds Pharmaceuticals Us's Cash & cash equivalent $ 8 Millions Visit APUS's Balance sheet
Source of APUS's Sales Visit APUS's Sales by Geography


Cumulative Apimeds Pharmaceuticals Us's Quick Ratio

APUS's Quick Ratio for the trailling 12 Months

APUS Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 1033.69 % 831.22 % 6236.95 % 2981.43 % -
Y / Y Cash & cash equivalent TTM Growth 307.86 % 3676.19 % 3462.19 % 3890.91 % -
Quick Ratio TTM 1.52 2.08 2.12 4.89 4.22
Total Ranking TTM # 17 # 17 # # #
Seq. Current Liabilities TTM Growth 35.63 % 41.01 % 311.3 % 44.12 % 11.41 %
Seq. Cash & cash equivalent TTM Growth -1.13 % 38.33 % 78.52 % 67.06 % 815.39 %

Quick ratio ranking by company, industry and sector >> Back to APUS Financial Strength Comparisons >> Go to Compare APUS Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q2 2026 to $7.17 millions, cumulative Quick Ratio decreased to 1.52 above the APUS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry APUS achieved the highest Quick Ratio. While overall ranking is unchanged compared to the previous 12 months at no. 17.

Explain Quick Ratio?
How much Cash & cash equivalents APUS´s has?
What are APUS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 17


trailing twelve months Quick Ratio Statistics
High Average Low
2.05 1.46 0.84
(Dec 31 2025)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Harmony Biosciences Holdings inc   3.17 $ 667.791  Millions$ 210.812  Millions
Pulmatrix Inc   3.15 $ 2.168  Millions$ 0.689  Millions
Nextcure Inc   3.13 $ 20.088  Millions$ 6.413  Millions
Dianthus Therapeutics Inc   3.13 $ 107.611  Millions$ 34.389  Millions
Tg Therapeutics Inc   3.02 $ 811.665  Millions$ 268.493  Millions
Dermata Therapeutics Inc   3.02 $ 4.413  Millions$ 1.462  Millions
Xilio Therapeutics Inc   2.99 $ 136.040  Millions$ 45.487  Millions
Cadrenal Therapeutics Inc  2.99 $ 4.476  Millions$ 1.497  Millions
Zevra Therapeutics Inc   2.99 $ 145.321  Millions$ 48.632  Millions
Inhibitor Therapeutics Inc   2.95 $ 0.516  Millions$ 0.175  Millions
Annovis Bio Inc   2.95 $ 18.736  Millions$ 6.359  Millions
Puma Biotechnology Inc   2.89 $ 144.164  Millions$ 49.825  Millions
Ptc Therapeutics inc   2.89 $ 2,229.082  Millions$ 771.068  Millions
Werewolf Therapeutics Inc   2.80 $ 21.987  Millions$ 7.863  Millions
Alzamend Neuro Inc   2.77 $ 7.591  Millions$ 2.739  Millions
Scienture Holdings Inc   2.71 $ 8.188  Millions$ 3.026  Millions
Acadia Pharmaceuticals Inc   2.65 $ 956.474  Millions$ 361.436  Millions
Edesa Biotech Inc   2.63 $ 10.300  Millions$ 3.910  Millions
Hepion Pharmaceuticals Inc   2.63 $ 1.629  Millions$ 0.620  Millions
Stoke Therapeutics Inc   2.62 $ 110.004  Millions$ 41.930  Millions
Elicio Therapeutics Inc   2.55 $ 23.480  Millions$ 9.202  Millions
Adc Therapeutics Sa  2.54 $ 219.107  Millions$ 86.332  Millions
Beone Medicines Ltd   2.50 $ 5,290.368  Millions$ 2,119.187  Millions
Ironwood Pharmaceuticals inc   2.41 $ 79.127  Millions$ 32.854  Millions
Schrodinger Inc   2.38 $ 413.739  Millions$ 173.845  Millions
Insmed Inc  2.37 $ 1,160.312  Millions$ 490.508  Millions
Biovie Inc   2.37 $ 8.977  Millions$ 3.796  Millions
Tao Synergies Inc   2.30 $ 2.368  Millions$ 1.032  Millions
Madrigal Pharmaceuticals Inc   2.24 $ 839.419  Millions$ 374.204  Millions
Rockwell Medical inc   2.23 $ 24.936  Millions$ 11.174  Millions

Date modified: 2026-09-12T06:29:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.